Application of MRI and contrast ultrasound in the diagnosis and differentiation of hepatocellular carcinoma and hemangioma

Abstract

Abstract: Objective To explore the practical utility of magnetic resonance diffusion-weighted imaging and contrast-enhanced ultrasound in the diagnosis and differentiation of hepatocellular carcinoma and hemangioma. Methods We retrospectively analyzed the clinical data of 86 patients with substantial hepatic space-occupying lesions from January 2018 to May 2020. Pathological examination confirmed 46 cases of hepatocellular carcinoma and 40 cases of hepatic hemangioma. MRI and contrast-enhanced ultrasound examinations were conducted to observe the imaging appearances of hepatocellular carcinoma and hemangioma. Additionally, contrast-enhanced ultrasound parameters (start time, peak time, and regression time) and MRI parameters (ADC, PF) of hepatocellular carcinoma and hemangioma were evaluated. The start of enhancement time, peak time, regression time, ADC, PF AUC, sensitivity, specificity, and Youden index were assessed for the diagnosis of hepatocellular carcinoma and hemangioma. Results The start time, peak time, regression time, ADC and PF of hepatocellular carcinoma patients were (10.34±1.89) s, (22.98±8.32) s, (36.85±12.32) s, (1.37±0.32) ×10^-3 s/mm², and (23.25±3.32) %, respectively. The initial enhancement time, peak time, regression time, ADC, PF were (14.59±4.25) s, (35.06±10.65) s, (52.05±15.75) s, (2.18±0.65) ×10^-3 s/mm², (30.18±5.98) %, respectively. The differences were statistically significant (P<0.05). Analysis of the ROC curve showed that the AUCs of start time, peak time, regression time, ADC, and PF in the diagnosis and differentiation of hepatocellular carcinoma and hemangioma were 0.746, 0.786, 0.747, 0.828, 0.833, P<0.05. The sensitivity was 100.00%, 100.00%, 95.70%, 58.70%, 71.70%, respectively. The specificity was 50.00%, 47.50%, 50.00%, 92.50% and 85.00%, respectively. Conclusion Both magnetic resonance diffusion-weighted imaging and contrast-enhanced ultrasound can provide reference information for the diagnosis and distinguishing between hepatocellular carcinoma and hemangioma. However, MRI is considered to be more applicable in this regard.

Key words: magnetic resonance diffusion-weighted imaging, contrast-enhanced ultrasound, hepatocellular carcinoma, hemangioma

XIE Yu-wen¹, ZHANG Quan-lu¹, WANG Ping-ping². Application of MRI and contrast ultrasound in the diagnosis and differentiation of hepatocellular carcinoma and hemangioma[J]. Chinese Hepatolgy, 2023, 28(10): 1195-1198.

References

[1] 吴晓贝,罗鸿昌,李开艳,等. 超声造影LI-RADS分类在肝细胞癌诊断中的应用价值[J]. 中华超声影像学杂志,2018,27(11):936-941.
[2] 徐肖静,吴俊,李惠,等. 超声造影引导常规超声检查阴性复发性肝细胞性肝癌射频消融近期疗效分析[J]. 实用医学杂志,2018,34(3):401-405.
[3] Kim J H, Joo I, Lee J M. Atypical appearance of hepatocellular carcinoma and its mimickers: how to solve challenging cases using gadoxetic acid-enhanced liver magnetic resonance imaging[J]. Korean J Radiol, 2019, 20(7):1019-1041.
[4] 胡健,刘明春,王瑜,等. 超声造影检查在甲胎蛋白阴性和阳性肝细胞癌诊断中的应用[J]. 肝脏,2020,25(11):1178-1180,1184.
[5] 卓涛,陈海燕,陈冬梅,等. 超声造影在微小肝细胞肝癌诊断中的应用价值[J]. 临床和实验医学杂志,2019,18(7):766-769.
[6] Zhang HX, Zhang XS, Zi-Xiang K, et al. Determination of hepatocellular carcinoma and characterization of hepatic focal lesions with adaptive multi-exponential intravoxel incoherent motion model[J]. Transl Oncol, 2018, 11(6):1370-1378.
[7] 芮春平,刘佳. 超声弹性成像联合超声造影在鉴别原发性及转移性肝癌中的应用[J]. 影像科学与光化学,2019,37(4):371-377.
[8] 雒大健,全艳,张志勇. 超声造影与彩色多普勒超声在肝实质性肿块诊断中的对比研究[J]. 中国超声医学杂志,2018,34(8):701-705.
[9] 李卫侠,林晓珠,张静,等. CT能谱成像在肝细胞肝癌与肝血管瘤鉴别诊断中的价值[J]. 放射学实践,2018,33(9):882-887.
[10] 徐亚丹,王文平,王群,等. 超声造影与增强磁共振在诊断肝上皮样血管内皮瘤中的联合应用[J]. 中华超声影像学杂志,2018,27(8):692-697.
[11] 冯俊,常凤玲. 超声造影LI-RADS分类标准在肝细胞癌鉴别及诊断中的应用[J]. 肝脏,2020,25(3):297-299.
[12] 鞠烨,刘爱连,李烨,等. 基于磁共振表观扩散系数图的纹理分析在鉴别肝癌与血管瘤上的可行性研究[J]. 中国医学计算机成像杂志,2018,24(5):446-451.
[13] 杨亮,顾玉明,徐浩,等. 超声造影与增强MRI在肝细胞癌TACE疗效评估中的应用价值[J]. 中华肝胆外科杂志,2020,26(9):683-686.

[1]	WANG Kai-li, HU Xiao-wei, YIN Jian, LIU Qing-yang, WANG Qiu-bo. Diagnosis and evaluation of serum midkine levels in response to TACE treatment in patients with hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1072-1074.
[2]	GE Shu, LIU Yang-yang. Contrast-enhanced ultrasonography and enhanced CT in differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1075-1078.
[3]	ZHANG Xiang, LI Ying-ying, TANG Qing, LI Wei, SUN Li-zhu. Evaluation value of CD8⁺ T lymphocyte level in immunotherapy efficacy in patients with advanced hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(9): 1084-1087.
[4]	NIE Bin, ZHAO Tie-jun, ZHANG Sheng-long. A prognostic analysis on the radical resection of primary hepatocellular carcinoma with microvascular invasion by different resection margin schemes [J]. Chinese Hepatolgy, 2023, 28(8): 921-923.
[5]	ZHANG Hai-rong, LI Jin-song, TIAN Xiu-li, HE Xin, JIANG Jue. A novel treatment on small hepatocellular carcinoma adjacent to large vessels by ultrasound assisted precision microwave ablation [J]. Chinese Hepatolgy, 2023, 28(8): 932-934.
[6]	HU Zhi-qiang, MEN Fen-yong, LIU Dong. A correlation analysis between immune-related adverse events and the curative effect caused by immune checkpoint inhibitors on patients with advanced primary Hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 935-937.
[7]	XU Jia-pin, SHAO Chun-yan, LIU Di-fa, XU Ya-chun. The value of diffusion weighted imaging of voxel incoherent motion in predicting microvascular invasion and evaluating the efficacy of TACE therapy on hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(8): 938-942.
[8]	YUAN Qing-gong, ZHANG Yan, LI Jun-hui, YANG Wen-bin. Effect of fibronectin type III domain containing 5 on the metastatic activity of HepG2 hepatoma cells in vitro and its mechanism [J]. Chinese Hepatolgy, 2023, 28(8): 943-946.
[9]	HUANG Qian, LI Ya-nan, ZENG Da-wu. Expression and prognostic value of ANLN, CYP2C9 and HMMR in hepatitis B virus-associated hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 775-780.
[10]	LI Gang, CAO Zhi-qun, NIU Shuai. Effect of TACE on serum tumor markers and recurrence risk after radical hepatocellular carcinoma resection at different time [J]. Chinese Hepatolgy, 2023, 28(7): 781-784.
[11]	CHEN Yong-ying, PENG Pan, XU Lei-lei. Application of SVM prediction model in judging the degree of pathological differentiation of primary hliver cancerepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(7): 785-788.
[12]	YANG Ya-meng, LUO Dan-feng. The inhibitory effects of mTOR inhibitor combined with ursodeoxycholic acid on the growth, immune escape, and Ras/ERK signaling pathway of hepatocellular carcinoma in rats [J]. Chinese Hepatolgy, 2023, 28(7): 789-793.
[13]	HAN Ting-chao, WANG Zhong, SHEN Meng-yuan, TANG Meng-ge, YU Jin-song. Impact of blood supply type on the three-year therapeutic effect of interventional embolitzation in patients with hepatic hemangioma [J]. Chinese Hepatolgy, 2023, 28(7): 833-836.
[14]	GUO Dan-dan, QIN Ling, GAO Weng-feng, YUAN Chun-wang, ZHANG Ying-hua, ZHANG Yong-hong. Correlation between the plasma levels of interleukin-33 and hepatocellular carcinoma, thermal ablation therapy [J]. Chinese Hepatolgy, 2023, 28(6): 665-667.
[15]	MA Bo-heng, WANG Xia, WU Ying. An evaluation of serum biochemical indexes, pathological characteristics and surgical treatment efficacy of sarcomatoid hepatocellular carcinoma [J]. Chinese Hepatolgy, 2023, 28(6): 676-679.